Agenus Inc. (AGEN) Stock’s Detailed Analysis

view original post

Agenus Inc. (NASDAQ:AGEN) has a beta value of 1.14 and has seen 4.42 million shares traded in the last trading session. The company, currently valued at $799.04M, closed the last trade at $3.03 per share which meant it gained $0.04 on the day or 1.34% during that session. The AGEN stock price is -124.09% off its 52-week high price of $6.79 and 17.49% above the 52-week low of $2.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.27 million shares traded. The 3-month trading volume is 4.38 million shares.

The consensus among analysts is that Agenus Inc. (AGEN) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.16.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Sporting 1.34% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/10/22 when the AGEN stock price touched $3.03 or saw a rise of 13.18%. Year-to-date, Agenus Inc. shares have moved -5.90%, while the 5-day performance has seen it change -12.68%. Over the past 30 days, the shares of Agenus Inc. (NASDAQ:AGEN) have changed -5.61%. Short interest in the company has seen 18.67 million shares shorted with days to cover at 4.37.

Wall Street analysts have a consensus price target for the stock at $10.00, which means that the shares’ value could jump 69.7% from current levels. The projected low price target is $7.00 while the price target rests at a high of $12.00. In that case, then, we find that the current price level is -296.04% off the targeted high while a plunge would see the stock gain -131.02% from current levels.

Agenus Inc. (AGEN) estimates and forecasts

Figures show that Agenus Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -46.28% over the past 6 months, with this year growth rate of 96.19%, compared to 7.80% for the industry. Revenue growth from the last financial year stood is estimated to be 255.20%.

4 analysts offering their estimates for the company have set an average revenue estimate of $37.74 million for the current quarter. 2 have an estimated revenue figure of $15.1 million for the next quarter concluding in Mar 2022. Year-ago sales stood $31.27 million and $11.72 million respectively for this quarter and the next, and analysts expect sales will grow by 20.70% for the current quarter and 28.90% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.40% over the past 5 years.

AGEN Dividends

Agenus Inc. is expected to release its next earnings report between March 14 and March 18 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Agenus Inc. (NASDAQ:AGEN)’s Major holders

Insiders own 11.64% of the company shares, while shares held by institutions stand at 47.98% with a share float percentage of 54.30%. Investors are also buoyed by the number of investors in a company, with Agenus Inc. having a total of 224 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 16.58 million shares worth more than $87.06 million. As of Sep 29, 2021, Blackrock Inc. held 6.46% of shares outstanding.

The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 14.94 million shares as of Sep 29, 2021. The firm’s total holdings are worth over $78.41 million and represent 5.82% of shares outstanding.

>> 7 Top Picks for the Post-Pandemic Economy <<

Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Sep 29, 2021, the former fund manager holds about 3.28% shares in the company for having 8.43 million shares of worth $44.27 million while later fund manager owns 5.84 million shares of worth $30.65 million as of Sep 29, 2021, which makes it owner of about 2.27% of company’s outstanding stock.